{
    "symbol": "TXMD",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-15 09:46:04",
    "content": " Our total net revenue for the quarter was $28.6 million, an increase of 24% over the second quarter of 2021. With the proceeds from these efforts, the company has been able to repay $120 million of debt during the second quarter and TXMD is now a far more focused business, dedicated to advancing the health of women throughout all stages of their lives. Our total revenue for the quarter was $28.6 million, an increase of $5.6 million or 24.2% compared to the second quarter 2021. For the quarter, sales of ANNOVERA were $18.3 million, an increase of $8.7 million or 91.2% compared to the second quarter of 2021. Sales in IMVEXXY were $6.7 million for the quarter, a decrease of $3.2 million or 32.2% compared to the second quarter 2021. Sales at BIJUVA were $2.7 million for the second quarter, an increase of $0.5 million or 23.1% compared to the second quarter of 2021. Prescription vitamin sales were $0.9 million for the second quarter, a decrease of $0.5 million or 35.5% compared to the second quarter of 2021. Gross profit for the second quarter of 2022 was $23.8 million, an increase of $5 million or 26.2% compared to the second quarter of 2021, and this is due primarily to the increase in product revenue. Total operating expenses for the quarter were $42.7 million, a decrease of $11.4 million or 21.1% compared to the second quarter of 2021. Selling and marketing costs were $23.7 million for the second quarter, a decrease of $8.5 million or 26.4% compared to the second quarter of 2021, due to lower brand spending for IMVEXXY and ANNOVERA, reduced compensation and employee benefit expense and lower consulting expenditures, partially offset by higher education, conference and software development costs. General and administrative costs were $17.4 million for the quarter, a decrease of $2.5 million or 12.4% compared to the second quarter of 2021. R&D costs were $1.6 million during quarter, a decrease of $0.4 million or 21.4% compared to the second quarter of 2021. Other non-operating expenses totaled $11.7 million, an increase of $4.2 million or 56.7% compared to non-operating expenses of $7.5 million for the second quarter of 2021. Net cash used in operating activities was $15.4 million for the second quarter, and as of June 30, 2022 we had $26.3 million in cash."
}